Depatuxizumab mafodotin (Depatux-M) is an antibody-drug conjugate derived from the monoclonal antibody mAb 806, which selectively targets EGFR amplification and EGFRvIII specifically in GBM tissue [88]. The gene discussed is EGFR; the disease is glioblastoma.